What is the project?
GSK’s partnership with Save the Children supports work to save children’s lives in 41 different countries. Two multimillion-pound flagship programmes, in the Democratic Republic of Congo and Kenya, tackle severe challenges in the supply of and demand for effective healthcare for mothers and their babies.
How is the company involved?
Combining GSK's scientific expertise with Save the Children's experience of vulnerable communities allows the partnership to employ research and development to help some of the hardest-to-reach mothers and children. For example, the partnership has reformulated chlorhexidine, an ingredient in a GSK mouthwash, to create a gel that is used to prevent neonatal sepsis, a major cause of new-born death.
Through GSK's skill-based volunteer scheme Pulse, more than 100 GSK employees have worked with Save the Children across 32 countries. GSK employees also support the partnership through the fundraising programme Orange United, with 444 Orange United Ambassadors from 51 countries. Total employee fundraising since the launch in 2013 is now more than £3m.
What has it achieved?
Between September 2016 and August 2017, 14,738 children in Kenya and 39,537 children in the DRC were reached though the partnership’s life-saving interventions, with more than 2.6 million children reached to date. More than 97,600 children have been fully immunised, 187,800 children treated for malaria, pneumonia or diarrhoea, and more than 16,000 health workers have been trained.
The 20% Reinvestment Initiative, whereby GSK reinvests profits to improve healthcare infrastructure, allows Save the Children to deliver programmes in 14 countries. In each country the partnership has strengthened the core health infrastructure by building the capacity of front-line health workers. In Mali in 2017, the project influenced national government to double its health worker budget, leading to the recruitment of 900 skilled health workers.